LIS downtime: restoring molecular lab operations after a crash

Ransomware, server failure, a botched upgrade, a failed network switch, or a problem in an upstream interface can stop the electronic workflow in seconds. The uptime target may look reassuring on paper, but it offers little help once the system is unavailable. What remains is the protocol the laboratory built before the failure.

The cost of getting recovery wrong is not abstract. Downtime creates manual work, delays results, interrupts charge capture, and increases regulatory exposure when the outage window is poorly documented. Molecular workflows compound the problem because they carry specimen lineage across multiple instruments, software pipelines, and review steps. Lose the chain of custody for a chemistry panel and you lose a number. Lose it for an NGS run and you may lose the evidence supporting the diagnostic claim.

A laboratory information system failure contingency plan therefore cannot stop at keeping the bench running. It has to preserve three things at once: the identity of every specimen, the clinical usability of every result, and the evidence that connects the two after the system comes back.

Maintaining Specimen Lineage During System Outages

A chemistry analyzer can pause. A molecular plate cannot.

Lineage depth is what separates the two. A molecular assay carries DNA or RNA extracts across batch identifiers, extraction plate maps, instrument run IDs, and, for labs running NGS, multiplexing indices that must reconcile downstream in the bioinformatics pipeline. Every transition produces metadata that normally lives in the LIS. When the system drops, that metadata becomes paper, and the paper becomes part of the audit trail.

The first operational decision is to declare the outage formally rather than allowing each section to improvise its own workaround. The declaration should establish the downtime start time, identify the person authorized to activate the paper process, and specify where the central downtime record will be kept. A molecular lab may continue testing, pause selected assays, or redirect urgent work, but those decisions need to be visible in one place.

The laboratory should maintain three parallel logs from the moment the outage is declared. Each has a specific function and a specific failure mode if skipped.

• Specimen accession log. Keyed to the pre-numbered paper requisition series activated at downtime. It captures the accession number, collection time, ordering provider, specimen type, patient identifiers, and the physical location of the aliquot in the extraction rack, freezer, or tube carrier.
• Batch-processing log. Tracks extraction plate IDs, the instruments used, run start and stop times, the performing technologist, and the relationship between source specimens and derived materials. In a molecular workflow, this is the record that explains how a tube became an extract, how the extract entered a plate, and how the plate became a reportable run.
• Reagent and control log. Captures lot numbers, expiration dates, control identities, and QC outcomes for every run performed offline. A valid result generated without recorded QC is a result the laboratory may not be able to defend during review.

The paper record has to follow the specimen, not remain in a folder at accessioning. If a sample moves from accessioning to extraction, the movement should be recorded. If an extract is transferred to storage or a plate is released to an instrument area, that transition should be traceable. The objective is not to reproduce every screen in the LIS on paper. It is to preserve the links that make the final result credible.

The downtime binder is an operational instrument

Pre-numbered requisitions are not optional. Labs that improvise slips during an outage make later reconciliation harder because nothing anchors the paper record to a planned numbering scheme. The requisition series should be pre-allocated, stored in a known physical location alongside the downtime binder, and tied to a documented downtime start time when the outage is declared.

A usable binder is more than a stack of blank forms. It should contain the current accessioning forms, specimen movement logs, batch worksheets, result communication forms, critical-value documentation, charge templates, contact information for IT and registration, and the escalation path for assays that cannot safely wait. Older versions should be removed. A form that no longer matches the laboratory’s accessioning fields or instrument workflow is not a backup; it is another source of reconciliation work.

The paper process also needs rules for corrections. Erasing an entry or replacing a page may make the record look tidy, but it destroys the sequence an auditor needs to understand. Corrections should remain legible, follow the laboratory’s document-control practice, and identify who made the change and when. The same discipline applies to handwritten patient identifiers, run numbers, and result values. A rushed correction without an attributable trail creates a second problem after the original outage is over.

During an LIS outage, paper is not a temporary convenience. It is the system of record until the electronic record can be reconstructed.

A molecular lab should also define what happens to work already in progress when the failure occurs. A specimen that has been accessioned electronically but has not reached extraction is different from a specimen already on an extraction plate. A plate that has completed amplification is different from a plate awaiting review. Each state needs a clear paper representation so the recovery team does not restart work unnecessarily or assume that an incomplete process was completed.

This is particularly important for tests that cross departmental boundaries. The wet-lab team may know that an extraction was completed, while the bioinformatics team sees no corresponding case in its queue. During a system outage, the paper record must bridge that gap. It should identify the source specimen, the derived material, the analytical step completed, and the next controlled handoff.

Manual Documentation and Urgent Result Reporting Strategies

When the LIS is down, the result still has to reach the clinician. The method changes; the obligation does not.

During an extended outage, laboratories may scan instrument printouts into the patient’s chart through the EMR or hand-deliver paper copies to the ordering unit for STAT and critical values. This is a workaround, not a substitute for reconstruction. Results communicated outside the LIS must later be reconciled into the permanent record once the system is restored. A printout can support immediate communication, but by itself it does not recreate the complete electronic audit trail.

The communication record should show what was reported, when it was reported, who communicated it, and who received it. For a molecular result, the record may also need to identify the specimen, assay, run, and interpretation status. A preliminary instrument output is not necessarily the same thing as a final result released by an authorized reviewer. If the laboratory communicates a provisional finding because the LIS is unavailable, that status should be unmistakable.

Triage is mandatory. Not every molecular assay can be held to the same turnaround expectation during an outage. Labs should predefine a downtime priority order, with clinically urgent infectious-disease testing generally considered before routine oncology NGS or hereditary panels when deferral is clinically acceptable. The priority list should live in the downtime binder, not in someone’s memory.

The decision to continue or defer an assay should account for more than clinical urgency. The laboratory also has to consider whether the complete workflow can be controlled manually. A test that depends on several software handoffs, automated plate maps, or an external analysis pipeline may be unsafe to continue if those dependencies cannot be documented. In that case, deferral is not a failure of service; it is a controlled decision to protect specimen identity and result integrity.

The laboratory should separate the person performing manual entry from the person checking the completed record whenever staffing permits. This is especially important for molecular results, where a transcription error in a variant, pathogen target, or detected/not-detected field can change the clinical meaning of the report. A second review does not replace source documentation, but it can catch errors introduced during recovery.

Staffing continuity

Recovery is a staffing problem as much as a systems problem. Manual documentation takes longer than normal electronic processing, and post-restoration back-entry creates an additional clerical queue whose size depends on the number and complexity of specimens affected. The laboratory should identify in advance who covers each function during an outage: accessioning, extraction, result entry, charge reconciliation, and clinical communication.

Cross-training bench technologists on the relevant LIS result-entry screens is useful because technical staff may be the people back-loading data once the system returns. The recovery plan should not assume that an external contractor or a single super-user will be available for every shift.

Assignments should be explicit rather than implied by job title. One person may coordinate the downtime log, another may control paper requisitions, and a third may maintain the list of specimens awaiting communication. If everyone assumes that someone else is tracking the same queue, specimens disappear into the gap between sections.

Shift coverage should also extend to the patient registration team. Their work to reconstruct or modify patient stay accounts in the restored LIS is a prerequisite for the laboratory’s later activity. If registration is short-staffed on the recovery day, result back-entry may stop before it starts.

The laboratory should preserve a handoff between shifts during the outage. The handoff needs to identify specimens received, specimens in process, completed runs, results communicated, unresolved identification questions, and supplies or forms running low. A clean handoff prevents the next shift from treating an incomplete extraction or unreviewed run as if it were ready for reporting.

Executing Systematic Data Reconciliation Post-Restoration

Restoration is where many laboratories lose control of the event. The system may be reachable while the affected records remain incomplete, duplicated, or disconnected from the paper documentation.

The order of operations matters. Patient registration teams should first establish or modify the patient stay accounts in the restored LIS. Admissions, discharges, and transfers that occurred during downtime have to be reconstructed before laboratory personnel post historical results. Otherwise, backlogged results may land in an unlinked or incorrect encounter.

Once the patient accounts are clean, technical staff can move to result back-entry. This is manual, line by line, and it is often the slowest part of recovery. For molecular assays, back-entry should include not only the final interpreted result but also the run-level metadata needed to explain how that result was produced: extraction date, instrument ID, reagent lot, performing technologist, and relevant QC flags. The exact fields depend on the laboratory’s workflow and validation requirements, but the principle is consistent: the restored record must match the work actually performed during downtime.

Reconciliation should begin with a controlled inventory, not with whoever happens to open the LIS first. The downtime coordinator needs a complete list of:

• paper accessions created during the outage;
• completed, interrupted, and incomplete runs;
• results communicated outside the LIS;
• charges prepared for later entry;
• specimens still physically present in the laboratory;
• unresolved identity, order, or encounter questions.

These lists become the control totals for recovery. Without them, the team can confirm that individual entries look correct while still missing an entire group of specimens.

A practical sequencing framework for a molecular laboratory is:

1. Verify patient-account integrity across the outage window.

2. Confirm that the restored LIS is accepting entries correctly before loading the full backlog.

3. Back-load specimen-level accession data from the downtime log into the LIS.

4. Match every paper accession to the corresponding patient, order, specimen type, and collection details.

5. Enter results manually, using a consistent sequence such as accession-number or batch order.

6. Re-enter or attach the run-level information needed to connect the result to extraction, amplification, sequencing, or another analytical step.

7. Re-run or relink bioinformatics workflows when the analysis output must be associated with restored LIS specimen identifiers.

8. Flag for secondary review every result originally communicated outside the LIS.

9. Reconcile the final result list against the downtime specimen log before closing the event.

The duration of this work depends on staffing depth, the number of affected specimens, the complexity of the assays, and the number of NGS cases in the queue. A short outage affecting straightforward targeted assays may be reconciled differently from a longer outage involving multiple sequencing runs. The precise duration matters less than the existence of a defined endpoint.

Recovery is not complete when the LIS is reachable. It is complete when the laboratory can account for every affected specimen and explain every result, charge, correction, and communication.

Protecting data integrity after restoration

A restored system can create a false sense of safety. If an interface reconnects and new specimens are flowing normally, staff may assume that historical data has also been recovered. It has not. Downtime records and live records can coexist in the same system while remaining internally inconsistent.

The reconciliation team should look for duplicate accessions, missing orders, mismatched collection times, results attached to the wrong encounter, and records that contain a result but no corresponding run documentation. For NGS, the review should extend to sample sheets, plate maps, run identifiers, and the relationship between the reported case and the underlying analysis. For PCR or targeted assays, the relevant evidence may be the extraction batch, amplification run, control status, and instrument output.

A discrepancy should be documented rather than silently corrected. The record needs to show what was found, how it was resolved, who reviewed the resolution, and whether a corrected report or amended charge was required. Quiet fixes may make the database look cleaner, but they make the audit trail harder to defend.

The laboratory should also preserve the original downtime documents according to its retention and document-control policies. Scanning the paper record may improve access, but scanning does not eliminate the need to establish how the image relates to the electronic entry. The final record should make it possible to move from a restored result to its source worksheet, instrument output, QC documentation, and communication record.

Managing Financial Integrity via Bulk-Charge Templates

Revenue recovery is a separate workstream from result recovery, and it runs in parallel.

The standard tool is a bulk-charge spreadsheet: a controlled template that captures the patient, medical record number, encounter or admission information, test code, date of service, and other fields required by the laboratory’s billing workflow for specimens processed offline. Once the LIS is restored, the template can be uploaded or entered as a batch charge-capture file, depending on the system’s capabilities.

The template supports charge capture. It does not recreate the result record, and it does not guarantee reimbursement. Payment remains dependent on accurate billing, payer rules, claim acceptance, adjudication, and other steps outside the bulk upload itself.

That distinction is a common point of confusion in post-downtime operations. Charge capture and result reporting are different recovery tasks. A charge may be entered correctly while the patient chart still lacks the final result. Conversely, a result may be back-entered while the associated charge is missing. Both records must be reconciled against the same specimen and encounter.

Before uploading a bulk-charge file, the recovery team should compare it with the downtime accession log and the final LIS result list. The review should identify:

• specimens processed but not yet charged;
• charges associated with canceled or deferred tests;
• duplicate entries created during manual recovery;
• mismatched patient or encounter identifiers;
• tests whose final performed procedure differs from the original order;
• charges requiring correction after a result or order review.

The person preparing the file should not be the only person approving it. A second review can focus on identity, test code, date of service, and the relationship between the charge and the documented work. The level of review should reflect the laboratory’s financial controls and the risk of duplicate or unsupported billing.

Bulk-charge recovery protects the financial record of the outage, but it is not a substitute for result reconciliation—and it cannot promise payment by itself.

Financial integrity also depends on documenting exceptions. If a specimen was received but testing was deferred, that status should be clear. If a test was repeated because the original run was invalid, the recovery record should distinguish the repeat from the initial attempt. If an order was canceled after clinical review, the charge workflow should not treat it as a completed service simply because a paper form exists.

The billing team, laboratory, registration staff, and IT recovery lead should use the same control totals. They do not need identical working spreadsheets, but they do need a shared definition of what counts as received, processed, resulted, communicated, and billable. Otherwise, each department can close its own queue while the overall event remains unresolved.

Regulatory Compliance and Audit Trail Preservation

An outage does not suspend the laboratory’s obligations. It changes how the laboratory demonstrates control.

The audit trail should establish when the outage began, who authorized downtime procedures, which forms and numbering series were activated, what testing continued, what was deferred, how urgent results were communicated, and when normal operations resumed. It should also show the reconciliation work performed after restoration and the disposition of discrepancies.

For molecular testing, the evidence needs to reach beyond accession and final result. Depending on the assay, the retained record may need to connect the patient and specimen to extraction, amplification or sequencing, controls, reagent lots, instrument runs, analysis files, interpretation, authorization, and communication. The laboratory does not need to recreate the LIS screen exactly on paper, but it does need to preserve the relationships that support the result.

A useful post-event review asks several direct questions:

• Can the laboratory account for every specimen received during the outage?
• Can it distinguish specimens that were tested from those that were deferred or canceled?
• Can every reported result be linked to a specimen, run, QC record, and authorized review?
• Can every externally communicated result be found in the restored patient record?
• Can every charge be linked to documented work and the correct encounter?
• Are corrections attributable, dated, and explainable?
• Does the final record show where the paper source documents are stored?

The review should include both technical and administrative staff. IT can explain the failure and restoration sequence, but IT alone cannot determine whether specimen lineage was preserved. The laboratory can explain the analytical workflow, but it may not see duplicate encounters or billing exceptions. Registration, billing, quality, and clinical communication teams each hold part of the evidence.

The laboratory should then revise the contingency plan based on what actually happened. Forms may have been missing fields. A contact list may have contained outdated numbers. A handoff may have failed between accessioning and the molecular section. An assay may have depended on an interface no one had included in the deferral rules. These are not minor observations. They are the practical limits of the current laboratory information system failure contingency plan.

Rehearsal should test the complete chain rather than only the moment when the LIS becomes unavailable. The exercise should include specimen receipt, paper accessioning, plate setup, result communication, patient-account reconstruction, result back-entry, charge capture, discrepancy review, and event closure. A protocol that works only at the bench is incomplete. Molecular diagnostic workflow continuity depends on what happens before and after the analytical step.

The recovery protocol is part of the assay

An LIS outage exposes whether the laboratory understands its own workflow as a connected system or as a series of screens. In molecular diagnostics, that distinction is decisive. Specimens become aliquots, extracts, plates, runs, analysis objects, and reports. If the links between those states disappear during downtime, the laboratory may still produce output without being able to prove what the output means.

The answer is not to force every assay to continue under every condition. It is to define which work can be controlled manually, which work must pause, and what evidence is required before a result can be released. The strongest protocols are specific about paper identifiers, specimen movement, run documentation, urgent communication, staffing, patient-account recovery, result entry, charge capture, and audit closure.

That is the practical meaning of LIS downtime recovery protocols for molecular labs. The goal is not merely to bring the software back online. The goal is to restore a defensible connection between the specimen, the analysis, the result, the patient record, and the financial and regulatory evidence surrounding them.